Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LPO | P22079 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1937006 | 0.81 | SMN1; SMN2 (0.36) | KMT2ALPOFDPSKDM4EALDH1A1 | |
| SCHEMBL28386445 | 0.78 | CHRNB2 (0.40) | KMT2ACHRNB2CHRNA4LPOFDPS | |
| SCHEMBL1682004 | 0.78 | CHRNB2 (0.40) | KMT2ACHRNB2CHRNA4LPOFDPS | |
| SCHEMBL6673530 | 0.77 | CHRNB2 (0.39) | KMT2ACHRNB2CHRNA4TSHRLPO | |
| SCHEMBL8536744 | 0.73 | ARG1 (0.32) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL28324902 | 0.72 | CHRNB2 (0.36) | KMT2ACHRNB2CHRNA4LPOFDPS | |
| SCHEMBL16991360 | 0.72 | CHRNB2 (0.40) | KMT2ACHRNB2CHRNA4LPOFDPS | |
| SCHEMBL3012029 | 0.71 | KMT2A (0.50) | KMT2ATSHRKDM4EALDH1A1PKM | |
| SCHEMBL2804720 | 0.70 | KMT2A (0.52) | KMT2ATSHRKDM4EALDH1A1PKM | |
| SCHEMBL30831127 | 0.69 | NAMPT (0.42) | KMT2ATSHRLPOFDPSKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111435705-B | Repairing agent and repairing method thereof and method for preparing photoelectric film | 杭州纤纳光电科技有限公司 | 2023-04-07 | — | — | CN | claimed |
| US-20210147466-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF | TEVA CZECH INDUSTRIES S.R.O. (CZ) | 2021-05-20 | — | — | US | claimed |
| EP-3634972-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF | Teva Czech Industries s.r.o. (CZ) | 2020-04-15 | — | — | EP | claimed |
| WO-2019014286-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF | TEVA CZECH INDUSTRIES S.R.O. (CZ) | 2019-01-17 | — | — | WO | claimed |
| CN-114502565-A | Process for producing bicyclic phosphoramidites | 第一三共株式会社 | 2022-05-13 | — | — | CN | disclosed |
| US-20210147466-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF | TEVA CZECH INDUSTRIES S.R.O. (CZ) | 2021-05-20 | — | — | US | disclosed |
| EP-3634972-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF | Teva Czech Industries s.r.o. (CZ) | 2020-04-15 | — | — | EP | disclosed |
| WO-2019014286-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF | TEVA CZECH INDUSTRIES S.R.O. (CZ) | 2019-01-17 | — | — | WO | disclosed |
| EP-1828218-B1 | SYNTHESIS OF PHOSPHITYLATED COMPOUNDS USING A QUATERNARY HETEROCYCLIC ACTIVATOR | GIRINDUS AG (DE) | 2014-04-30 | — | — | EP | disclosed |
| US-20130303745-A1 | Synthesis of oligonucleotides | LANGE MEINOLF (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20130281682-A1 | SYNTHESIS OF PHOSPHITYLATED COMPOUNDS USING A QUATERNARY HETEROCYCLIC ACTIVATOR | GIRINDUS AG (DE) | 2013-10-24 | — | — | US | disclosed |
| US-20120316328-A1 | SYNTHESIS OF PHOSPHITYLATED COMPOUNDS USING A QUATERNARY HETEROCYCLIC ACTIVATOR | GIRINDUS AG (DE) | 2012-12-13 | — | — | US | disclosed |
| EP-2152723-A1 | SYNTHESIS OF OLIGONUCLEOTIDES | Girindus AG (DE) | 2010-02-17 | — | — | EP | disclosed |
| WO-2009066883-A1 | ADHESIVE COMPOSITION, AND OPTICAL MEMBER, SURFACE PROTECTIVE SHEET | CHEIL INDUSTRIES INC. (KR) | 2009-05-28 | — | — | WO | disclosed |
| WO-2008141682-A1 | SYNTHESIS OF OLIGONUCLEOTIDES | GIRINDUS AG (DE) | 2008-11-27 | — | — | WO | disclosed |
| EP-1828218-A1 | SYNTHESIS OF PHOSPHITYLATED COMPOUNDS USING A QUATERNARY HETEROCYCLIC ACTIVATOR | Girindus AG (DE) | 2007-09-05 | — | — | EP | disclosed |
| CN-1840600-A | Adhesive composition, adhesive sheets and surface protective film | NITTO DENKO CORP (JP) | 2006-10-04 | — | — | CN | disclosed |
| WO-2006064039-A1 | SYNTHESIS OF PHOSPHITYLATED COMPOUNDS USING A QUATERNARY HETEROCYCLIC ACTIVATOR | GIRINDUS AG (DE) | 2006-06-22 | — | — | WO | disclosed |
| EP-0737358-A1 | PHOTOELECTROCHEMICAL CELL AND ELECTROLYTE THEREFOR | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) | 1996-10-16 | — | — | EP | disclosed |
| WO-1995018456-A1 | PHOTOELECTROCHEMICAL CELL AND ELECTROLYTE THEREFOR | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) | 1995-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303745-A1 | Synthesis of oligonucleotides | RNGTT, POLRMT, CPSF6 | KMT2A 1057/4885CHRNB2 4634/4885CHRNA4 4264/4885 |
| US-20120316328-A1 | SYNTHESIS OF PHOSPHITYLATED COMPOUNDS USING A QUATERNARY HETEROCYCLIC ACTIVATOR | ARAF, ATIC, PFKFB3 | KMT2A 1546/4885CHRNB2 3727/4885CHRNA4 3490/4885 |
| US-20210147466-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF | UNG, SAMHD1, ALKBH1 | KMT2A 853/4885CHRNB2 4882/4885CHRNA4 4850/4885 |
| US-20130281682-A1 | SYNTHESIS OF PHOSPHITYLATED COMPOUNDS USING A QUATERNARY HETEROCYCLIC ACTIVATOR | ARAF, ATIC, HK2 | KMT2A 1545/4885CHRNB2 3680/4885CHRNA4 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.